The new bivalent shot targets the Omicron BA.4/BA.5 subvariants and is intended to be used as a booster dose for people 18 years of age and older. It comes two months after Health Canada approved a bivalent booster from Moderna that targeted the Omicron BA.1 subvariant and the original strain. Health Canada says a bivalent enhancer triggers “a strong immune response” against the two latest subvariants of Omicron, as well as the original strains of the SARS-CoV-2 virus. The National Immunization Advisory Committee says Omicron BA.4 and BA.5 are the dominant strains in circulation. They have several key mutations from the original SARS-CoV-2 virus, leading NACI to strongly recommend bivalent enhancers targeting Omicron. On October 7, Health Canada approved Pfizer-BioNTech’s bivalent booster for people 12 years of age and older. It also targets the Omicron BA.4 and BA.5 sub-variants. This report by The Canadian Press was first published on November 3, 2022. SHARE: COME TO THE DISCUSSION Anyone can read the conversations, but to contribute, you must be a registered Torstar account holder. If you don’t have a Torstar account yet, you can create one now (it’s free) Sign in Register Conversations are the opinions of our readers and are subject to our Code of Conduct. The Star does not endorse these views.
title: “Health Canada Approves Updated Version Of Moderna S Covid 19 Booster Vaccine " ShowToc: true date: “2022-12-15” author: “Nancy Gooslin”
The new bivalent shot targets the Omicron BA.4/BA.5 subvariants and is intended to be used as a booster dose for people 18 years of age and older. It comes two months after Health Canada approved a bivalent booster from Moderna that targeted the Omicron BA.1 subvariant and the original strain. Health Canada says a bivalent enhancer triggers “a strong immune response” against the two latest subvariants of Omicron, as well as the original strains of the SARS-CoV-2 virus. The National Immunization Advisory Committee says Omicron BA.4 and BA.5 are the dominant strains in circulation. They have several key mutations from the original SARS-CoV-2 virus, leading NACI to strongly recommend bivalent enhancers targeting Omicron. On October 7, Health Canada approved Pfizer-BioNTech’s bivalent booster for people 12 years of age and older. It also targets the Omicron BA.4 and BA.5 sub-variants. This report by The Canadian Press was first published on November 3, 2022. SHARE: COME TO THE DISCUSSION Anyone can read the conversations, but to contribute, you must be a registered Torstar account holder. If you don’t have a Torstar account yet, you can create one now (it’s free) Sign in Register Conversations are the opinions of our readers and are subject to our Code of Conduct. The Star does not endorse these views.
title: “Health Canada Approves Updated Version Of Moderna S Covid 19 Booster Vaccine " ShowToc: true date: “2022-11-01” author: “Jennifer Perez”
The new bivalent shot targets the Omicron BA.4/BA.5 subvariants and is intended to be used as a booster dose for people 18 years of age and older.
It comes two months after Health Canada approved a bivalent booster from Moderna that targeted the Omicron BA.1 subvariant and the original strain.
Health Canada says a bivalent enhancer triggers “a strong immune response” against the two latest subvariants of Omicron, as well as the original strains of the SARS-CoV-2 virus.
The National Immunization Advisory Committee says Omicron BA.4 and BA.5 are the dominant strains in circulation.
They have several key mutations from the original SARS-CoV-2 virus, leading NACI to strongly recommend bivalent enhancers targeting Omicron.
On October 7, Health Canada approved Pfizer-BioNTech’s bivalent booster for people 12 years of age and older. It also targets the Omicron BA.4 and BA.5 sub-variants.
This report by The Canadian Press was first published on November 3, 2022.
